Novel therapeutics in myeloproliferative neoplasms
Abstract Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN), i.e., polycythemia vera (PV), essential thrombocythemia (ET), and...
Main Authors: | Sangeetha Venugopal, John Mascarenhas |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-020-00995-y |
Similar Items
-
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
by: Giuseppe Gaetano Loscocco, et al.
Published: (2024-07-01) -
The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
by: Helna Pettersson, et al.
Published: (2023-08-01) -
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01) -
The Role of New Technologies in Myeloproliferative Neoplasms
by: Giuseppe A. Palumbo, et al.
Published: (2019-04-01) -
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
by: Li Huo, et al.
Published: (2023-01-01)